Screener
Denali Therapeutics Inc. DNLI Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s accounts payable?
- Denali Therapeutics Inc. (DNLI) reported accounts payable of $11.81M in Q2 2026.
- How has Denali Therapeutics Inc.'s accounts payable changed year-over-year?
- Denali Therapeutics Inc.'s accounts payable increased by 8.9% year-over-year, from $10.84M to $11.81M.
- What is the long-term trend for Denali Therapeutics Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s accounts payable has grown at a -14.0% compound annual growth rate (CAGR), from $1.07M to $505K.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Denali Therapeutics Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude